Icodextrin
is a glucose polymer used in peritoneal dialysis to help in improved clearance
and ultrafiltration. Laboratory and metabolic effects of icodextin is important
to know( especially the effect on glucose, Na and serum osmolarity)
There are
a few that are important to remember
1.
The predominant circulating metabolites of
icodextrin are maltose , maltotriose , and maltotetraose, with little glucose
released in the systemic circulation due to the absence of circulating maltase.
The release of glucose from the metabolized polymers occurs predominantly
during the intra-cellular metabolism of maltose or other polymers by way of
cellular enzymes involved in carbohydrate metabolism.
2.
The “glucose load” arising from the use of
icodextrin is “functionally invisible” to the peritoneal cavity and systemic
circulation, and its predominant systemic exposure is intracellular.
3.
In contrast to the acute hyperglycemia and
hyperinsulinemia associated with glucose-based solutions, icodextrin does not
lead to hyperglycemia or hyperinsulinemia following its intraperitoneal
administration.
4.
Point of care glucose testing might not be
accurate when using icodextrin and serum glucose values should be used for
insulin management. Maltose interferes with glucose assays that utilize
glucose dehydrogenase enzymes of the pyrroloquinolinequinone class (GDH PQQ),
causing falsely elevated readings. The overestimation of glycemia is likely due
to the presence of maltose and other oligosaccharide metabolites of icodextrin
in the systemic circulation and the reaction of GDH-PQQ with the free reducing
group of the glucose molecule located at the end of each saccharide chain.
5.
The decline in serum sodium and chloride
associated with icodextrin therapy is caused mainly by a dilutional effect
resulting from blood levels of icodextrin metabolites, particularly maltose and
maltotriose. The presence of osmotically active particles in the vascular
compartment is sufficient to cause a slight shift in water from the
interstitial and cellular compartments to the vascular compartment, resulting
in the dilutional hyponatremia (sometimes called hypertonic hyponatremia). It
is like having hyperglycemia or mannitol induced hyponatremia.
6.
Use of icodextrin has been associated with a
slight increase in plasma osmolality in some studies. It can last up to 2 weeks
after discontinuing icodextrin
7.
A small increase in mean serum alkaline
phosphatase has been reported in some studies
of icodextrin Increases in alkaline phosphatase are not associated
with true liver or billiary disease.
8.
Icodextrin interferes with amylase activity
measurements by acting as a competitive inhibitor in the amylase activity
assay.
No comments:
Post a Comment